v3.26.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND PRACTICES (Details Narrative)
6 Months Ended 12 Months Ended
Oct. 10, 2025
¥ / shares
shares
May 01, 2025
USD ($)
May 01, 2025
JPY (¥)
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2026
JPY (¥)
shares
Jun. 30, 2025
JPY (¥)
shares
Dec. 31, 2025
JPY (¥)
Jun. 30, 2026
JPY (¥)
Product Information [Line Items]                
Foreign currency transactions       Translations of amounts in the unaudited interim condensed consolidated balance sheets, unaudited interim condensed consolidated statements of income, and unaudited interim condensed consolidated statements of cash flows from JPY into US$ as of and for the six months ended June 30, 2026 are solely for the convenience of the reader and were calculated at the noon buying rate of US$1 = JPY162.61, as published in H.10 statistical release of the United States Federal Reserve Board. No representation is made that the JPY amounts could have been, or could be, converted, realized, or settled into US$ at such rate or at any other rate. Translations of amounts in the unaudited interim condensed consolidated balance sheets, unaudited interim condensed consolidated statements of income, and unaudited interim condensed consolidated statements of cash flows from JPY into US$ as of and for the six months ended June 30, 2026 are solely for the convenience of the reader and were calculated at the noon buying rate of US$1 = JPY162.61, as published in H.10 statistical release of the United States Federal Reserve Board. No representation is made that the JPY amounts could have been, or could be, converted, realized, or settled into US$ at such rate or at any other rate.      
Cash             ¥ 0 ¥ 0
Cash               20,500,000
Allowance for credit losses of accounts receivable       $ 40,300 ¥ 6,553,222   7,405,870  
Total deferred expenses       142,111     22,177,409 23,108,750
Impairment of long-lived assets         0   ¥ 0  
Deferred offering costs       1,908,972       ¥ 303,679,188
Registration fees       204,348 33,229,082 ¥ 32,516,324    
Advertising expenses       1,420,270 230,950,049 66,105,459    
Grant income       $ 106,453 ¥ 17,310,392 ¥ 9,399,558    
Dilutive shares | shares       3,000 3,000 3,000    
Accounts Receivable [Member] | Customer Concentration Risk [Member] | No Customer [Member]                
Product Information [Line Items]                
Concentration risk percentage       10.00% 10.00%   10.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | No Customer [Member]                
Product Information [Line Items]                
Concentration risk percentage       10.68% 10.68% 10.00%    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | No Vendor [Member]                
Product Information [Line Items]                
Concentration risk percentage       10.00% 10.00%      
Accounts Payable [Member] | Customer Concentration Risk [Member] | A Vendor [Member]                
Product Information [Line Items]                
Concentration risk percentage       19.80% 19.80%   21.60%  
Accounts Payable [Member] | Customer Concentration Risk [Member] | B Vendor [Member]                
Product Information [Line Items]                
Concentration risk percentage             10.10%  
Accounts Payable [Member] | Customer Concentration Risk [Member] | C Vendor [Member]                
Product Information [Line Items]                
Concentration risk percentage       13.30% 13.30%      
IPO [Member]                
Product Information [Line Items]                
Sale of units in initial public offering | shares 1,250,000              
Sale of units per share | ¥ / shares ¥ 4.00              
Private Placement [Member]                
Product Information [Line Items]                
Net proceeds   $ 4,302,198 ¥ 658,666,480